Lipoprotein(a) has long been recognized as a critical marker for people at risk of cardiovascular disease. However, the health care industry has lacked the tools to tackle the problem.
Read More
Roche is developing the tests in partnership with Indianapolis-based Eli Lilly and Co. Earlier this year, the U.S. Food and Drug Administration granted a breakthrough device designation to the product.
Read More
Brad Moore succeeds Matt Sause, who was appointed CEO of Roche Diagnostics globally in October.
Read More
Matt Sause, president and CEO of Roche Diagnostics North America since 2019, has been named CEO of Roche Diagnostics and a member of the corporate executive committee. He will relocate to the parent company’s offices in Basel, Switzerland.
Read More
Roche said Indiana would receive a new manufacturing facility for continuous glucose monitoring and expansion and upgrades at existing pharmaceutical, diagnostics and distribution operations.
The test, one of the first of its kind, is designed to reach patients who may forgo traditional screening because of lack of access, past trauma or embarrassment.
The the Swiss drugmaker will face off in the obesity area with leaders Novo Nordisk A/S and Indianapolis-based Eli Lilly and Co.
Roche and Lilly said they believe the test could play an important role in improving access to early and accurate Alzheimer’s diagnosis.
Wong’s appointment comes just a few weeks after BioCrossroads released a report warning that Indiana’s life-science sector is starting to lag the nation in growth and market share and will require a focused effort to stay competitive.
Roche has come under pressure to improve its pipeline with medicines it can commercialize soon as a windfall of revenue from products used in the COVID-19 pandemic comes to an end.
Brigitte Fernandes is suing Roche for sex discrimination and national origin discrimination. A Roche spokesman declined to comment, citing pending litigation.
In a statement to IBJ, Roche said it hopes to display “supportive and inspiring messages” visible from I-69 as part of a new corporate initiative.
The contract is part of the U.S. government’s effort to double its procurement of rapid COVID-19 tests to be delivered for free to Americans through a forthcoming federal website.
Matthew Sause took the helm of the 4,500-person Roche Diagnostics’ North American operations in Indianapolis in November 2019—just four months before the World Health Organization declared a pandemic and much of the planet went into lockdown.
Crystal Derrick, who was a national account manager in Roche’s diabetes division, had accused the company of illegally paying insurance company Humana Inc. for access to certain formularies.
Roche Diagnostics’ North American headquarters in Indianapolis will be the shipping and distribution hub for all tests distributed in the United States, the company said.
Indianapolis-based Roche Diagnostics said Monday that it has begun shipping an initial order of 400,000 COVID-19 test kits to a network of more than 30 hospital and laboratories.
Spark Therapeutics Inc. will give Roche Holding a chance to make up ground in a field where single treatments may command more than $1 million. It also snaps up an asset that rivals like Novartis might have coveted.
Castleton remains central Indiana’s most expansive retail corridor, but does its retail focus—and its car-centric layout—suggest trouble lies ahead?
The company, which employs more than 3,000 on the northeast side, has been struggling on the diabetes side of its business. To bounce back, it is investing heavily in diagnostics, and is working to commercialize several products it hopes will be game-changers.
The “Roche Academy” will provide mentors, internships and special curriculum to biology and chemistry undergrads, along with financial incentives and a job offer after graduation.
Roche Holding AG—the Basel, Switzerland-based parent of Indianapolis-based Roche Diagnostics—has enlisted a little green gremlin to help rescue its diabetes business after a decade of declining sales.
Roche Group is rolling out a new blood-glucose meter and a savings program for test strips, which it says it will make diabetes care more affordable.
Two Indianapolis-based subsidiaries of Swiss pharmaceutical giant Roche Group are accusing a group of pharmacies and supply houses of engaging in an elaborate scheme to defraud Roche of millions of dollars worth of sales on diabetes test strips.
